Furthermore, several combinations showed repurposing potential: for instance, combined MK-1775 (WEE1 and PLK1 inhibitor) and irinotecan (TOP1 inhibitor) treatment, screened with camptothecin as the TOP1 inhibitor, had a 26.7% synergy rate in MSS colon cancer (versus 6.7% in microsatellite unstable (MSI)), is currently in a trial in rhabdomyosarcoma and blastomas (NCT02095132). The gene discussed is TOP1; the disease is blastoma.